CA2477878C - Peptides selectively lethal to malignant and transformed mammalian cells - Google Patents

Abstract

The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or tranformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membrane-penetrating leader sequence are also provided.

Description

PEPTIDES SELECTIVELY LETHAL TO MALIGNANT AND
TRANSFORMED MAMMALIAN CELLS

This application is a continuation-in-part application of Application Serial No.

09/827,683,_filed April 5, 2001, this application claims the benefit of U.S.
Provisional - = -Application No. 60/363,785, filed March 12, 2002, and U.S. Serial No.
09/827,683 claims the benefit of U.S. Provisional Application Serial No. 60/195,102, filed April 5, 2000.

BACKGROUND OF THE INVENTION

This invention relates to therapeutic modalities for treatment of neoplastic disease.

More specifically, this invention involves synthetic peptides that selectively destroy malignant and transformed cells, and a method for treatment of neoplastic disease based thereon.

The p53 protein is a vital regulator of the cell cycle. It blocks the oncogenic effects of a number of oncogene proteins that induce mitosis, in part by blocking transcription of proteins that induce mitosis and by inducing the transcription of proteins that block mitosis, and promote apoptosis. Absence of the p53 protein is associated with cell transformation and malignant disease. Haffner, R & Oren, M. (1995) C1117.
Op/n. Genet.

Dev. 5: 84-90.

The p53 protein molecule consists of 393 amino acids. It includes domains that bind to specific sequences of DNA in a DNA-binding domain that consists of residues 93-313. The crystal structure of this region has been determined by x-ray crystallography.

Residues 312-393 are involved in the formation of homotetramers of the p53 protein.

=

=

Residues 1-93 are involved in regulation of the activity and half life of the p53 protein.
The p53 protein binds to another important regulatory protein, the MDM-2 protein.
The MDM-gene that encodes the MDM-2 protein is a known oncogene. The MDM-2 protein forms a complex with the p53 protein, which results in the degradation of the p53 protein by a ubiquination pathway. The p53 protein binds to MDM-2 protein using an amino acid sequence that includes residues 14-22 of the p53 protein, which are invariant.
The entire MDM-2 protein binding domain of the p53 protein spans residues 12-26.
Haffner, R & Oren, M. (1995) Curr. Opin. Genet. Dev. 5: 84-90.
Considering that the MDM-2 protein is the expression product of a known oncogene, it is not surprising that MDM-2 protein is a very important regulatory protein.
Moreover, overexpression or amplification of MDM-2 protein has been found in 40-60%
of human malignancies, including 50% of human breast tumors. It has been suggested that formation of a complex between the p53 protein and the MDM-2 protein may result in the inhibition of transcription activity of the p53 protein, and thus the anti-tumor effect of the molecule by blocking of an activation domain of the p53 protein, or of a DNA
binding site within it. More generally, these and other experimental observations have been interpreted as suggesting that the anti-tumor effect of the p53 protein might be enhanced by peptides capable of interfering with the binding of the MDM-2 protein to the p53 protein. Indeed, a number of investigators have suggested that the MDM-2/p53 complex might be a target for rational drug design. See, e.g., Christine Wasylyk et al., 11p53 Mediated Death of Cells Overexpressing MDM2 by an Inhibitor of MDM2 Interaction with p5311, Oncogene, 18, 1921-34 (1999), and U.S. Patent No. 5,770,377 to Picksley et al.

SUMMARY OF THE INVENTION

The present invention provides a peptide comprising at least about six .

contiguous amino acids of the amino acid sequence: PPLSQETFSDLWKIL (SEQ ID

NO:1), or an analog or derivative thereof, wherein said peptide or analog or derivative thereof is fused to a membrane-penetrating leader sequence and is selectively lethal to - .
malignant or transformed cells.

Examples of such peptides include PPLSQETFSDLWKLL (SEQ ED NO:1) or an analog or derivative thereof, PPLSQETFS (SEQ ID NO:2) or an analog or derivative thereof and ETFSDLWKLL (SEQ ID NO:3) or an analog or derivative thereof. In order to be transported across a cell membrane and selectively kill a malignant or transformed cell, the leader sequence is preferably positioned at the carboxyl terminal end of the Peptide, analog, or derivative thereof. Preferably, the leader sequence comprises predominantly positively charged amino acid residues. Examples of leader sequences which may be used in accordance With the present invention include but are not limited to penetratin, Arg8, TAT of H1V1, D-TAT, R-TAT, SV40-NLS, nucleoplasmin-NLS, REV REV (34-50), FHV

coat (35-49), BMV GAG (7-25), HTLV-II REX (4-16), CCMV GAG (7-25), P22N (14-30), Lambda N (1-22), Delta N (12-29), yeast PRP6, human U2AF, human C-FOS
(139-164), human C-JUN (252-279), yeast GCN4, and p-vec. Preferably, the leader sequence is the penetratin sequence from antetznapedia protein having the amino acid sequence 2,0 KKWKNIRRNQFWVICVQRG (SEQ ID NO:4).

Pharmaceutical compositions comprising at least one of the subject peptides admixed with a pharmaceutically acceptable carrier are also provided. In addition, methods for treating neoplastic disease in a subject i.e., selectively killing malignant or neoplastic cells in a subject, are provided. In one embodiment, the method comprises administering to the subject, a therapeutically effective amount of a peptide comprising at least about six contiguous amino acids of the amino acid sequence: =

PPLSQEFFSDLANKLL (SEQ ID NO:1), or an analog or derivative thereof, wherein said _ =

peptide or analog or derivative thereof is fused at its carboxy terminal end to a membrane-penetrating leader sequence and is selectively lethal to malignant or transformed cells. In another embodiment, the method comprises administering to the subject, a therapeutically effective amount of at least one peptide having the sequence set forth in SEQ
ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, or an analog or derivative thereof, wherein a membrane-penetrating leader sequence is fused to the carboxy terminal end of the peptide, analog, or derivative thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 graphically depicts the in vivo tumor-inhibiting effect of PNC-28 (SEQ ID

NO:3 fused at its carboxy terminal end to SEQ ID NO:4) in homozygous NU/NU
mice xenotransplanted with pancreatic carcinoma cells. The arrow with a star indicates the time of s.c. pump implantation on day 13 (precisely 13.5) during the tumor growth period.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, it has been discovered that malignant and transformed cells are selectively destroyed by administration of a synthetic peptide comprising a sequence of amino acids within the p53 protein and a leader sequence as a single continuous polypeptide chain. The mechanism of action appears to be independent _ . . .

of the p53 protein binding to the MDM-2 protein, as the p53 peptide selectively kills transformed cells that do not produce the p53 protein at all. The p53 peptide also selectively kills malignant and transformed cells that express normal or elevated levels of the p53 protein without killing normal cells.
In accordance with the present invention, there are provided compositions comprising peptides corresponding to all or a portion of amino acid residues 12-26 of human 1353. This region is known to contact the mdm-2 protein and adopts an a-helical conformation when bound to mdm-2. When fused on the carboxy-terminal end with a membrane-penetrating leader sequence, the subject peptides selectively kill malignant and transformed human cells.
In a first aspect of the invention, there is provided a peptide comprising at least .
about six contiguous amino acids of the following amino acid sequence:
PPLSQETFSDLWKLL (SEQ ID NO:1), wherein the peptide comprising at least about six contiguous amino acids is fused to a leader sequence. Preferably, the peptide comprises from at least about eight (8) to at least about fifteen (15) amino acid residues. In a preferred embodiment, a peptide comprising from at least about eight (8) to at least about 15 (fifteen) amino acids of the sequence set forth in SEQ ID NO:1 has the following amino acid sequence: PPLSQETFSDLWKLL (SEQ ID NO:1). In another preferred embodiment, a peptide comprising from at least about eight (8) to at least about 15 (fifteen) amino acids of the sequence set forth in SEQ 1D NO:1 has the following amino acid sequence: PPLSQETFS (SEQ ID NO:2). In still another preferred embodiment, a peptide comprising from at least about eight (8) to at least about fifteen (15) amino acids of the sequence set forth in SEQ ID NO:1 has the following amino acid sequence:
ETFSDLWKLL (SEQ ID NO:3).
Leader sequences which function to import the peptides of the invention into a cell may be derived from a variety of sources. Preferably, the leader sequence comprises predominantly positively charged amino acid residues since a positively charged leader sequence stabilizes the alpha helix of a subject peptide. Examples of leader sequences which may be linked to the peptides of the present invention are described in Futaki, S. et al (2001) Arginine-Rich Peptides, J. Biol. Chem. 276,:5836-5840, and include but are not limited to the following membrane-penetrating leader sequences (numbering of the amino acid residues making up the leader sequence of the protein is indicated parenthetically immediately after the name of the protein in many cases):
penetratin (KKWKMRRNQFWVKVQRG)(SEQ ID NO:4); (Arg)8 or any poly-R from (R)4-(R)16; HIV-1 TAT(47-60) (YGRICKRRQRRRPPQ)(SEQ ID NO:5); D-TAT
(GRKKRRQRRRPPQ) (SEQ ID NO:6); R-TAT G(R)9PPQ(SEQ EI) NO:7);
SV40-NLS (PKKKRKV)(SEQ ID NO:8); nucleoplasrnin-NLS
(KRPAAJKKAGQAKKKK)(SEQ ID NO:9); REV REV (34-50)-(TRQARRNRRRRWRERQR)(SEQ ID NO:10); FHV (35-49) coat-(RRRRNRTRRNRRRVR)(SEQ ID NO:11); BMV GAG (7-25)-(KMTRAQRRAAARRNRWTAR)(SEQ ID NO:12); HTLV-II REX 4-16-(TRRQRTRRARRNR)(SEQ ID NO:13); CCMV GAG (7-25) -(KLTRAQ TR)(SEQ ID NO:14); P22 N (14-30)(NAKTRRHERRRKLAIER)(SEQ ID NO:15); LAMBDA N (1-22)(MDAQTRRRERRAEKQAQWKAAN)(SEQ ID NO:16);
Phi N (12-29) (TAKTRYKARRAELIAERR)(SEQ ID NO:17);
YEAST PRP6 (129-124) (TRRNKRNRIQEQLNRK) (SEQ ID NO:18);
HUMAN U2AF (SQMTRQARRLYV)(SEQ ID NO:19); HUMAN C-FOS (139-164) KRRIRRERNMMAAAKSRNRRRELTDT (SEQ NO:20);
HUMAN C-JUN (252-279) (RLKAERKRMRNRIAASKSRKRKLERIAR)(SEQ ID
NO:21); YEAST GCN4 (KRARNTEAARRSRARKLQR_MKQ)(SEQ ID NO:22);
KLALKLALKALKAALKLA(SEQ ID NO:23); p-vec LLIILRRRIR_KQAKAHSK(SEQ
ID NO:24). Other membrane penetrating leader sequences may also be used. Such sequences are widely available and are described e.g., in Scheller et al.
(2000) Eur. J.
Biochern. 267:6043-6049, and Elmquist et al., (2001) Exp. Cell Res. 269:237-244.
Preferably, the positively charged leader sequence of the penetratin leader sequence of antennapedia protein is used. This leader sequence has the following amino acid sequence: KKWKMRRNQFWVKVQRG (SEQ ID NO:4). Preferably, the leader sequence is attached to the carboxyl terminal end of the p53 peptide to enable the synthetic peptide to kill transformed and malignant cells.
Structurally related amino acid sequences may be substituted for the disclosed sequences set forth in SEQ ID NOs: 1, 2, 3, or 4 in practicing the present invention. Any of the sequences set forth in SEQ ID NOs: 1, 2 or 3, including analogues or derivatives thereof, when joined with a leader sequence, including, but not limited to the sequence set forth in SEQ ID NO: 4, will be referred to herein as either a "synthetic peptide" or "synthetic peptides." Rigid molecules that mimic the three dimensional structure of these synthetic peptides are called peptidomimetics and are also included within the scope of this invention. Alpha helix stabilizing amino acid residues at either or both the amino or carboxyl terminal ends of the p53 peptide may be added to stabilize the alpha helical conformation which is known to be the conformation of this region of the p53 protein when it binds to the MDM-2 protein. Examples of alpha helical stabilizing amino acids include Leu, Glu (especially on the amino terminal of the helix), Met and Phe.
Amino acid insertional derivatives of the peptides of the present invention include amino and/or carboxyl terminal fusions as well as intra-sequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in a subject peptide although random insertion is also possible with suitable screening of the resulting product.
Deletional variants may be made by removing one or more amino acids from the sequence of a subject peptide. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place.
Typical substitutions are those made in accordance with the following Table 1:

Suitable residues for amino acid substitutions Original Residue Exemplary Substitutions Ala (A) Ser Arg (R) Lys Asn (N) Gln; His Asp (D) Glu Cys (C) Ser Gin (Q) Asn Glu (E) Asp Gly (G) Pro His (H) Asn; Gin Ile (I) Leu; Val Leu (L) Ile; Val Lys (K) Arg; Gin; Glu Met (M) Leu; Ile Phe (F) Met; Leu; Tyr . =
Ser (S) Thr Thr (T) Ser 7 - Trp (W) Tyr Tyr (Y) Trp; Phe Val (V) Ile; Leu When the synthetic peptide is derivatised by amino acid substitution, the amino =

acids are generally replaced by other amino acids having like properties such as hydrophobicity, hydrophilicity, electronegativety, bulky side chains and the like. As used herein, the terms "derivative", "analogue", "fragment", "portion" and "like molecule" refer .

to a subject peptide having the amino acid sequence as set forth in SEQ ID
NOs:1, 2, 3, or 4, having an amino acid substitution, insertion, addition, or deletion, as long as said derivative, analogue, fragment, portion, or like molecule retains the ability to enter and selectively kill transformed or neoplastic cells.

The synthetic peptides of the present invention may be synthesized by a number of known techniques. For example, the peptides may be prepared using the solid-phase technique initially described by Merrifield (1963) in J. Am. Chem. Soc.
85:2149-2154.

Other peptide synthesis techniques may be found in M. Bodanszky et al. Peptide Synthesis, John Wiley and Sons, 2d Ed., (1976) and other references readily available to those skilled in the art. A summary of polypeptide synthesis techniques may be found in J.
Sturart and J.S. Young, Solid Phase Peptide Synthesis, Pierce Chemical Company, Rockford, Ill., 9 =

(1984). Peptides may also be synthesized by solution methods as described in The Proteins, Vol. II, 3d Ed., Neurath, H. et al., Eds., pp. 105-237, Academic Press, New York, N.Y. (1976). Appropriate protective groups for use in different peptide syntheses are described in the texts listed above as well as in J.F.W. McOmie, Protective Groups in Organic Chemisny, Plenum Press, New York, N.Y. (1973). The peptides of the present - -invention may also be prepared by chemical or enzymatic cleavage from larger portions of the p53 protein or from the full length p53 protein. Likewise, leader sequences for use in the synthetic peptides of the present invention may be prepared by chemical or enzymatic cleavage from larger portions or the full length proteins from which such leader sequences are derived.

Additionally, the peptides of the present invention may also be prepared by recombinant DNA techniques. For most amino acids used to build proteins, more than one coding nucleotide triplet (codon) can code for a particular amino acid residue. This property of the genetic code is known as redundancy. Therefore, a number of different nucleotide sequences may code for a particular subject peptide selectively lethal to malignant and transformed mammalian cells. The present invention also contemplates a deoxyribonucleic acid (DNA) molecule that defines a gene coding for, i.e., capable of expressing a subject peptide or a chimeric peptide from which a peptide of the present invention may be enzymatically or chemically cleaved.

When applied to cells grown in culture, synthetic peptides are selectively lethal to malignant or transformed cells, resulting in dose dependent reduction in cell number. The effect is observable generally within two to three and at most 48 hours. A
line of rat pancreatic acinar cells (BMRPA.430) grown in culture was transformed with K-ras. The normal cell line displays the architecture typical of pancreatic acinar cells;
the transformed cells (TUC-3) lack the differentiated morphology of acinar cells, appearing as typical pancreatic cancer cells. When BMRPA.430 cells were treated with a synthetic peptide with the primary structure of SEQ ID NO:1 coupled to leader sequence SEQ ID
NO:4, at a _- -dosage of 50p,g/m1, the cells were not affected. However, when TUC-3 cells were treated with a peptide with the primary structure of SEQ ID NO:1 coupled to leader sequence SEQ

ID NO:4, at a dosage of 100 pg/ml, they died within three to four days.
Similar results were obtained when the same experiment was performed but SEQ ID NO:1 was substituted with either SEQ II) NO:2, or SEQ ID NO:3. Additionally, transformed and malignant cell death was observed in human breast carcinoma cell lines and Melanoma and HeLa cells treated with a synthetic peptide with the primary structure of SEQ
ID NO:1 coupled to leader sequence SEQ ID NO:4, at a dosage of 100 g/mi. In contrast, the same synthetic peptide at the same dosage had no effect on non-malignant and non-transformed human breast or fibroblast cell lines.

When the leader sequence set forth in SEQ ID NO:4 was positioned at the carboxy terminal end of PNC29, a control protein having the following amino acid sequence:

MPFSTGKRIMLGE (SEQ ID NO: 25), there was no effect on malignant or normal cells.

Additionally, the peptide having the amino acid sequence as set forth in SEQ
ID

NO:3 fused at the carboxy terminal end to the leader peptide set forth in SEQ
ID NO:4, has no effect on the ability of human stem cells to differentiate into hematopoietic cell lines in the presence of growth factors. This indicates that this peptide will not be injurious to =

CA 02477878 2010-06-01 =

bone marrow cells when administered as a chemotherapeutic agent. See Kanovsky et al., (October 23, 2001) PrOC. Nat. Acad. Sci. USA 98(22);12438-12443.

When cultured cancer cells were treated with a peptide with the primary structure of SEQ ID NO:1 without a leader sequence attached, at a dosage of 100 p.g/rnl, the cells were unaffected. Similarly, when cultured cancer cells were treated with leader sequence SEQ ID NO:4, the presently preferred leader sequence, at the same dosage, the cell were also unaffected. These results indicate that the leader sequence of the synthetic peptide allows the synthetic peptide to cross the cellular membranes of treated cells and that the effect of the synthetic peptide is necessarily intracellular.

In order to determine whether the synthetic peptides acted by interfering with the binding of the p53 protein and the MDM-2 protein, the synthetic peptides were tested on transformed colorectal adenocarcinoma cells that had been rendered incapable of making the p53 protein by homozygous deletion. Surprisingly, the synthetic peptides selectively killed the transformed cells, but had no effect on the normal cells. These results indicate that the mechanism of action appears to be independent of the p53 protein binding to the MDM-2 protein, as the p53 peptide selectively kills transformed cells that do not produce the p53 protein at all. These results indicate that interference with binding of the p53 protein to the MDM-2 protein may not be the mechanism by which synthetic peptides cause selective death of malignant and transformed cells. Although the synthetic peptides disclosed herein, their derivatives, analogues, and peptidomimetic molecules are useful in _ .

the treatment of neoplastic disease such as cancer, the mechanism for action on transformed and malignant cells has not been discovered.

The peptides of the present invention are effective against neoplastic cells in vivo.

For example, mice having been xenotransplanted with the pancreatic carcinoma cells BMRPA1.TUC-3 and having developed tumor size of about 3-6 mm, have the size of such _ -tumors drastically reduced after administration of a subject synthetic peptide, e.g., a peptide having the amino acid sequence as set forth in SEQ ID NO:3 fused to a leader sequence at the carboxy terminal end.

Consistent with the observed properties of the peptides of the invention, the subject peptides may be used to selectively kill neoplastic or malignant cells, i.e.., cancer cells in animals, preferentially humans. The synthetic peptides of the present invention are thus administered in an effective amount to kill neoplastic cells in a subject animal or human.

The synthetic peptides of the present invention may be administered preferably to a human patient as a pharmaceutical composition containing a therapeutically effective dose of at least one synthetic peptide according to the present invention together with a pharmaceutical acceptable carrier. The term "therapeutically effective amount"
or "pharmaceutically effective amount" means the dose needed to produce in an individual, suppressed growth including selective killing of neoplastic or malignant cells, i.e., cancer cells.

Preferably, compositions containing one or more of the synthetic peptides of the present invention are administered intravenously for the purpose of selectively killing neoplastic cells, and therefore, treating neoplastic or malignant disease such as cancer.

Examples of different cancers which may be effectively treated using one or more the peptides of the present invention include but are not limited to: breast cancer, prostate cancer, lung cancer, cervical cancer, colon cancer, melanoma, pancreatic cancer and all solid tissue tumors (epithelial cell tumors) and cancers of the blood including but not limited to lymphomas and leukemias.
- _ =

Administration of the synthetic peptides of the present invention may be by oral, intravenous, intranasal, suppository, intraperitoneal, intramuscular, intradermal or subcutaneous administration or by infusion or implantation. When administered in such manner, the synthetic peptides of the present invention may be combined with other ingredients, such as carriers and/or adjuvants. There are no limitations on the nature of the other ingredients, except that they must be pharmaceutically acceptable, efficacious for their intended administration, cannot degrade the activity of the active ingredients of the compositions, and cannot impede importation of a subject peptide into a cell.
The peptide compositions may also be impregnated into transdermal patches, or contained in subcutaneous inserts, preferably in a liquid or semi-liquid form which patch or insert time-releases therapeutically effective amounts of one or more of the subject synthetic peptides.

The pharmaceutical forms suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The ultimate solution form in all cases must be sterile and fluid.

Typical carriers include a solvent or dispersion medium containing, e.g., water buffered aqueous solutions, i.e., biocompatible buffers, ethanol, polyols such as glycerol, propylene glycol, polyethylene glycol, suitable mixtures thereof, surfactants or vegetable oils.

=
Sterilization may be accomplished utilizing any art-recognized technique, including but not . limited to filtration or addition of antibacterial or antifungal agents.
Examples of such agents include paraben, chlorbutanol, phenol, sorbic acid or thimerosal.
Isotonic agents such as sugars or sodium chloride may also be incorporated into the subject compositions. . .
_ As used herein, a "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and the like. The use of such media and agents are well-known in the art.
Production of sterile injectable solutions containing the subject synthetic peptides is accomplished by incorporating one or more of the subject synthetic peptides described hereinabove in the required amount in the appropriate solvent with one or more of the various ingredients enumerated above, as required, followed by sterilization, preferably filter sterilization. In order to obtain a sterile powder, the above solutions are vacuum-dried or freeze-dried as necessary.
Inert diluents and/or assimilable edible carriers and the like may be part of the pharmaceutical compositions when the peptides are administered orally. The pharmaceutical compositions may be in hard or soft shell gelatin capsules, be compressed into tablets, or may be in an elixir, suspension, syrup or the like.
The subject synthetic peptides are thus compounded for convenient and effective administration in pharmaceutically effective amounts with a suitable pharmaceutically acceptable carrier in a therapeutically effective dosage. Examples of a pharmaceutically effective amount includes peptide concentrations in the range from about at least about 25ug/m1 to at least about 300 ug/ml.

A precise therapeutically effective amount of synthetic peptide to be used in the methods of the invention applied to humans cannot be stated due to variations in stage of neoplastic disease, tumor size and aggressiveness, the presence or extent of Metastasis, etc.
In addition, an individual's weight, gender, and overall health must be considered and will effect dosage. It can be generally stated, however, that the synthetic peptides of the present invention be administered in an amount of at least about 10 mg per dose, more preferably in an amount up to about 1000 mg per dose. Since the peptide compositions of the present invention will eventually be cleared from the bloodstream, re-administration of the pharmaceutical compositions is indicated and preferred.
The synthetic peptides of the present invention may be administered in a manner compatible with the dosage formulation and in such an amount as will be therapeutically effective. Systemic dosages depend on the age, weight, and condition of the patient and the administration route. An exemplary suitable dose for the administration to adult humans ranges from about 0.1 to about 20 mg per kilogram of body weight.
Preferably, the dose is from about 0.1 to about 10 mg per kilogram of body weight.
In accordance with the present invention, there is also provided a method of treating neoplastic disease. The method comprises administering to a subject in need of such treatment, a therapeutically effective amount of a synthetic peptide hereinbefore described, including analogs and derivatives thereof. Thus for example, in one embodiment, an effective amount of a peptide comprising at least about six contiguous amino acids as set forth in SEQ ID NO:1 or an analog or derivative thereof fused on its carboxy terminal end to a leader sequence may be administered to a subject. In another embodiment, an effective amount of a peptide comprising at least from about eight (8) to at least about ten (10) contiguous amino acids as set forth in SEQ ID NO:1 or an analog or derivative thereof, fused on its carboxy terminal end to a leader sequence, may be , administered to a subject. For example, an effective amount of a peptide having the amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof, fused on its carboxy terminal end to a leader sequence may be administered to a subject. An effective amount of a peptide having the amino acid sequence as set forth in SEQ ID NO:2 or an analog or derivative thereof, fused on its carboxy terminal end to a leader sequence may also be administered to a subject. In still another embodiment, an effective amount of a peptide having the amino acid sequence set forth in SEQ ID NO:3 or an analog or derivative thereof, fused on its carboxy terminal end to a leader sequence may be administered to a subject. In accordance with a method of treatment, a mixture of synthetic peptides may be administered. Thus, for example, in addition to administering one of the peptides, or analogs or derivatives thereof hereinbefore described in an effective amount, mixtures of two or more peptides or analogs or derivatives hereinbefore described may be administered to a subject.
The following examples further illustrate the invention and are not meant to limit the scope thereof.

=

EXAMPLE I

The following experiment was performed to compare effectiveness of subject peptides having the leader sequence attached to the amino terminal end. As described supra, peptides synthesized with a leader sequence on the carboxyl terminal promoted a-helix formation in the peptide, which is the active conformation of the p53 part of this _ -peptide when bound to MDM-2. As described supra, subject peptides having the amino acid sequences as set forth in SEQ ID NOs:1, 2, and 3 are strongly toxic to a wide variety of human cancer cells, including those that are homozygously p53 gene-deleted.
An a-helix probability profile for each peptide having the sequences set forth in SEQ ID NOs:1-3 was performed using two different methods, one using helix probabilities from the protein database (Karplus, K. et al., (1998) Bioinformatics 14:846-856), and the other using the Ising model based on helix nucleation (a) and growth (s), equilibrium constants determined experimentally from block copolymers for each of the twenty naturally occurring L amino acids, modified by inclusion of the effects of charges on these parameters as described in Vasquez, M., et al. (1987) Biopolymers 26:351-372 and Vasquez, M., et al., (1987) Biopolymers 26:373-393. Probability profiles indicated that if the leader sequence is on the amino terminal end, even though the peptide still transverses the cell membrane, the a-helical content is much lower.

The peptide having the sequence set forth in SEQ ID NO:3 was synthesized by solid phase synthesis with the leader sequence attached to the amino terminal end. This peptide is labeled PNC28' in Table 2 below. The PNC28' peptide was incubated with transformed pancreatic cancer (TUC-3) cells at three different concentrations, i.e., 25, 50 and 100 p,g/ml. After two weeks of incubation, at the highest dose of peptide, there was no cell death, and approximately half of the cells were seen to form acini and exhibited the untransformed morphological phenotype. The same phenomena were observed at 50 g/ml, and at 25 p,g/ml significantly fewer cells were seen to revert. In contrast, when the leader sequence was attached to the carboxyl terminal end of the peptide (PNC28 in Table _ 2), at dosages of 50 and 100 p,g/ml. 100% cell death occurred in about 4 days.

These results show that the leader sequence is preferentially added to the carboxyl terminal end of the MDM-2 portion of the p53 peptide to enable the peptide to cross the cell membrane and specifically kill malignant cells. In Table 2, the leader sequence is KKWKMRRNQFWVKVQRG (SEQ ID NO:4).

NAME p53 seq. PEPTIDE EFFECT

1. PNC 21 12-20 (PPLSQETFS) (SEQ ID NO:2)¨ Cytotoxic Leader 2. PNC 27 12-26 (PPLSQETFSDLWKLL) (SEQ ID Cytotoxic NO:1)¨ Leader 3. PNC 28 17-26 (ETFSDLWKLUSEQ ID NO:3) ¨ Cytotoxic Leader 4. PNC 28' 17-26 Leader (ETFSDLWKLL)(SEQ ID No cell death and reversion NO:3) These results indicate the uniqueness of the subject peptides. i.e., the leader or cluster of positively charged residues must be placed at the carboxy terminal end of any effector peptide for cancer cell toxicity.

EXAMPLE H

Nu/Nu mice (Harlan Laboratories, Indianapolis, IN, n=10) and weighing 20-22g, were xenotransplanted subcutaneously (s.c.) with live pancreatic carcinoma cells BMRPA1 .TUC-3 (1 x 106 cells/mouse) in the left hind region. Tumors were allowed to develop and grow and during daily examinations it was observed that all mice developed tumors with very similar growth rates.
After 12 days the tumors had reached sizes of 3 to 6 mm diameter and the mice were separated into two groups of 5 mice each. Each group was implanted s.c.
with Alzet osmotic pumps to deliver in a constant rate and over a defined period of 14 days a total volume of 0.095 ml volume of normal saline containing the respective peptide at a concentration of 20mWmouse. One group of mice received PNC-28 (the peptide having the amino acid set forth in SEQ ID NO:3) fused at its carboxy terminal end to the penetratin leader sequence (SEQ ID NO:4) and the other group of mice received PNC-29, a control peptide of similar size, having the following amino acid sequence:
MPFSTGICREMLGE (SEQ ID NO: 25). The pumps were filled according to the manufacturers guidelines and under sterile conditions The pumps were implanted s.c. on the left flank of the anaesthetized mice by creating a pocket underneath the mouse skin into which the tiny pumps were inserted. Each pocket was closed with a simple suture. From their inside chamber the pumps delivered continuously 0.25 1.11/ hr into each mouse. The mice were observed until they had recovered from the surgery when they were returned to =
the isolation ward of the animal facility. Since the animals were Nu/Nu mice and, thus, immuno-compromised they are highly susceptible when exposed to pathogens.
Surgery and all preceding and post-surgical treatments were therefore performed in a sterile hood environment.

As shown clearly in Figure 1, PNC-28 within a 48 to 72hr period of delivery itito the mouse effectively arrests tumor growth. In contrast, the control peptide PNC-29 had no effect.on normal or tumor cells. In PNC29-treated mice, tumors kept growing at a _ continuous rate resulting in tumors of 10 to 16 ram diameter over the 2 - week treatment and follow-up period when the pumps cease to release any more peptide solution.

Statistical analyses of the measurement of tumor size in both groups of mice has produced a significance between them of p<0.001.

EXAMPLE FEE

Using the same methodology of Example II, pumps were started at the same time as live pancreatic carcinoma cells BMRPALTUC-3 (1 x 106 cells/mouse) were .

xenotransplanted into mice (n---10). Five mice were administered PNC28 and 5 mice were _ -not treated at all (sham treated). Results are tabulated below.

Treatment 7 Days 14 Days 21 Days Tumor Size Sham treated 4.8 1.8 11.7 2.3 14.8 3.6 PNC-28 treated 3 + .6 3d .9 4.4 .8 EXAMPLE IV

Using the same methodology as described in Example II, live pancreatic carcinoma cells BMRPA1.TUC-3 (1 x 106 cells/mouse) were transplanted to the peritoneal cavity of five mice. Pumps were placed in the right shoulder region at the same time of tumor cell -transplantation. In all five mice, there were no visible tumors after three weeks.

The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.

Claims (12)

WHAT IS CLAIMED IS:

1. A composition comprising a peptide, the peptide consisting of the amino acid sequence: PPLSQETFSDLWKLL (SEQ ID NO:1) fused on its amino terminal end to a membrane-penetrating leader sequence, and a pharmaceutically acceptable carrier.

2. A composition comprising a peptide, the peptide consisting of the amino acid sequence: PPLSQETFS (SEQ ID NO:2) fused on its amino terminal end to a membrane penetrating leader sequence, and a pharmaceutically acceptable carrier.

3. A composition comprising a peptide, the peptide consisting of the amino acid sequence: ETFSDLWKLL (SEQ ID NO:3) fused on its amino terminal end to a membrane penetrating leader sequence, and a pharmaceutically acceptable carrier.

4. A composition comprising at least one peptide consisting of the amino acid sequence: PPLSQETFSDLWKLL (SEQ ID NO:1), PPLSQETFS (SEQ ID NO:2), or ETFSDLWKLL (SEQ ID NO:3), said peptide fused on its amino terminal end to a membrane penetrating leader sequence, and a pharmaceutically acceptable carrier.

5. The composition of any one of claims 1-4 wherein the membrane-penetrating leader sequence comprises the amino acid sequence: KKWKMRRNQFWVKVQRG
(SEQ ID NO:4).

6. The composition of any one of claims 1-4 wherein the membrane-penetrating leader sequence comprises positively charged residues.

7. The composition of any one of claims 1-4 wherein the membrane penetrating leader sequence is at least one of Arg 8, TAT of HIV1, D-TAT, R-TAT, SV40-NLS, nucleoplasmin-NLS, HIV REV, FHV coat, BMV GAG, HTLV-II, CCMV GAG, P22N, Lambda N, Delta N, yeast PRP6, human U2AF, human C-FOS, human C-JUN, yeast GCN4, or p-vec.

8. Use of a therapeutically effective amount of at least one peptide consisting of the amino acid sequence: PPLSQETFSDLWKLL (SEQ ID NO:1), PPLSQETFS (SEQ
ID NO:2), or ETFSDLWKLL (SEQ ID NO:3), said peptide fused on its amino terminal end to a membrane penetrating leader sequence, for treating neoplastic disease in a subject.

9. Use of at least one peptide consisting of the amino acid sequence:
PPLSQETFSDLWKLL (SEQ ID NO:1), PPLSQETFS (SEQ ID NO:2), or ETFSDLWKLL (SEQ ID NO:3), said peptide fused on its amino terminal end to a membrane penetrating leader sequence, for the manufacture of a medicament for treating neoplastic disease in a subject.

10. The use of claim 8 or 9, wherein the membrane penetrating leader sequence comprises the amino acid sequence KKWKMRRNQFWVKVQRG (SEQ ID NO:4).

11. The use of claim 8 or 9, wherein the membrane penetrating leader sequence comprises positively charged residues.

12. The use of claim 8 or 9, wherein the membrane penetrating leader sequence is at least one of Arg 8, TAT of HIV1, D-TAT, R-TAT, SV40-NLS, nucleoplasmin-NLS, HIV REV, FHV coat, BMV GAG, HTLV-II, CCMV GAG, P22N, Lambda N, Delta N, yeast PRP6, human U2AF, human C-FOS, human C-JUN, yeast GCN4, or p-vec.